AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Go back to AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis| AbbVie (NYSE: ABBV) | Delayed: 261.70 +4.58 (1.78%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $257.12 | 52 Week High | $68.12 | |||
| Open | $261.67 | 52 Week Low | $50.71 | |||
| Day High | $264.65 | P/E | 56.77 | |||
| Day Low | $260.10 | EPS | $4.61 | |||
| Volume | 3,238,233 | |||||
